)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Gabather
Gabather (GABA) investor relations material
Gabather Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary31 Aug, 2026
Executive summary
Initiated the first patient study (TOTEMS) with lead candidate GT-002 for schizophrenia spectrum, marking transition from preclinical to clinical phase; study is externally funded and underway at CNSR, Copenhagen.
Filed a new patent for a non-sedative sleep treatment, expanding the platform into a market estimated at over $10 billion globally.
Maintained focus on cost discipline and evaluating multiple financing options to secure resources for upcoming milestones.
Financial highlights
Net sales were 0 TSEK for both Q2 and H1 2026, unchanged year-over-year.
Operating loss for Q2 was -1,039 TSEK (improved from -1,342 TSEK YoY); H1 operating loss was -2,379 TSEK (worsened from -1,645 TSEK YoY).
Net result per share was -0.00 SEK for both Q2 and H1 (vs. -0.01 SEK YoY).
Cash flow for H1 was 542 TSEK (down from 2,126 TSEK YoY); cash and cash equivalents at period end were 3,685 TSEK (up from 3,143 TSEK at year-end 2025).
Equity at period end was 1,463 TSEK (up from 662 TSEK at year-end 2025); equity ratio improved to 32.22% (from 12.36% at year-end 2025).
Outlook and guidance
Focus for the remainder of 2026 is on supporting patient recruitment in TOTEMS, scientific publication of EEG/fMRI data, and advancing partnership discussions.
Ongoing evaluation of structured, non-dilutive, and partnership-based financing to secure funding for next value-creating milestones.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gabather
- First patient study for GT-002 launched, 4.2 MSEK raised, and liquidity secured for 2026.GABA
Q1 2026 - Operating loss narrowed, but further financing is needed to sustain operations into 2026.GABAQ4 2025
- Operating losses persist amid zero revenue and delayed clinical milestones; liquidity remains tight.GABAQ3 2025
- GT002 enters phase II for schizophrenia cognition; TO 7 warrants could raise 5.3 MSEK.GABAInvestor Update
- Operating loss narrowed, but liquidity remains a concern as clinical progress continues.GABAQ2 2025
- Operating loss reduced, but negative equity and urgent financing needs persist.GABAQ3 2024
- Losses widened and liquidity remains strained as Gabather advances GT-002 clinical trials.GABAQ2 2024
- Gabather launches a SEK 21.4 million rights issue and advances its neuropsychiatric drug pipeline.GABAInvestor Update
- SEK 21.4 million rights issue supports Phase II GT-002 trial and March 2025 investor events.GABAInvestor Update
Next Gabather earnings date
Q3 202627 Nov, 2026
Gabather
Next Gabather earnings date
Q3 202627 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Gabather AB is a pharmaceutical company dedicated to developing therapeutics for central nervous system diseases. The company focuses on creating novel drug candidates primarily for the treatment of neuropsychiatric disorders, including anti-psychotics, anti-depressants, anxiolytics, analgesics, and cognition-enhancing treatments. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.